financetom
Business
financetom
/
Business
/
Condom maker Church & Dwight's CEO Farrell to step down, will be replaced by CFO
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Condom maker Church & Dwight's CEO Farrell to step down, will be replaced by CFO
Sep 16, 2024 2:56 PM

Sept 16 (Reuters) - Church & Dwight ( CHD ) said on

Monday that its CEO Matthew Farrell will step down, ending a

nearly two-decade stint at the condom maker, and finance chief

Rick Dierker will take over the top executive's

responsibilities.

The executive change comes as consumer goods companies such

as Church & Dwight ( CHD ) have been hiking their prices in a bid to

defend their profit margins against higher costs in recent

years.

Last month, the Trojan condom maker said it expects

full-year sales and profit at the lower end of its previous

forecast due to consumer hesitancy on spending for its

higher-priced household and personal care products.

Rick Dierker, who currently serves as CFO will be promoted

to the CEO position on March 31 next year. He has held various

positions in an over 15-year stint at the Therabreath mouthwash

maker, and took over the finance chief role in 2016.

Matt Farrell started out as the company's CFO in 2006, and

has held executive positions at AlliedSignal, which adopted the

Honeywell ( HON ) name after taking it over in 1999.

The company said Farrell will continue to serve as chairman

of the board for a transition period.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Moleculin Biotech Shares Slump After Phase 1b/2 Trial of Annamycin Fails to Show Complete Responses
Moleculin Biotech Shares Slump After Phase 1b/2 Trial of Annamycin Fails to Show Complete Responses
Jun 4, 2025
01:50 PM EDT, 06/04/2025 (MT Newswires) -- Moleculin Biotech ( MBRX ) shares dropped about 19% in recent Wednesday trading after the company said no patients achieved complete response in the phase 1b/2 study of Annamycin for the treatment of soft tissue sarcoma lung metastases, a type of cancer. The trial, however, demonstrated a clinical benefit rate of 59.4%, primarily...
Biohaven Shares Rise on Drug Pipeline Update With Two Near-Market Candidates
Biohaven Shares Rise on Drug Pipeline Update With Two Near-Market Candidates
Jun 4, 2025
01:47 PM EDT, 06/04/2025 (MT Newswires) -- Biohaven ( BHVN ) shares were up over 4% in recent trading on Wednesday after the company said its two drug candidates are near market and it is doing phase three testing for four other indications. BHV-4157 for the treatment of spinocerebellar ataxia and BHV-2000 for spinal muscular atrophy are closer to the...
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Aug 17, 2025
SYDNEY, Aug 18 (Reuters) - Google agreed on Monday to pay a A$55 million ($35.8 million) fine in Australia after the consumer watchdog found it had hurt competition by paying the country's two largest telcos to pre-install its search application on Android phones, excluding rival search engines. The fine extends a bumpy period for the Alphabet-owned internet giant in Australia,...
NanoVibronix Names Doron Besser as CEO
NanoVibronix Names Doron Besser as CEO
Jun 4, 2025
01:46 PM EDT, 06/04/2025 (MT Newswires) -- NanoVibronix ( NAOV ) said Wednesday that Brian Murphy is retiring as chief executive officer and the board has appointed Doron Besser as CEO, effective immediately. Besser was CEO of ENvue Medical, which NanoVibronix ( NAOV ) acquired in February, according to a statement. Murphy will remain on the board as a director,...
Copyright 2023-2026 - www.financetom.com All Rights Reserved